Malaysia Adult Malignant Glioma Therapeutics Market Report 2022 to 2030

Malaysia Adult Malignant Glioma Therapeutics Market Analysis

$ 3999

The Malaysia Adult Glioma Therapeutics Market is valued at around $4 Mn in 2022 and is projected to reach $7 Mn by 2030, exhibiting a CAGR of 9.1% during the forecast period. The factors attributed to market growth such as an aging population, improved diagnosis, and heightened awareness, are subsequently driving the demand for therapeutic interventions and are providing new opportunities for the expansion of the glioma therapeutics market. Key players in the Malaysia Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Emcure, Sun Pharmaceuticals, AbbVie, Pharmaniaga etc. among others.

ID: IN10MYPH426 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Netal Patel

Buy Now

Malaysia Adult Malignant Glioma Therapeutics Market Executive Summary

The Malaysia Adult Glioma Therapeutics Market is valued at around $4 Mn in 2022 and is projected to reach $7 Mn by 2030, exhibiting a CAGR of 9.1% during the forecast period.

A particular kind of tumour known as a glioma develops in the glial cells of the brain and spinal cord, which make up the central nervous system. Glial cells give support and shielding to nerve cells; gliomas are malignancies derived from these cells. Benign (non-cancerous) or malignant (cancerous) gliomas are both possible. Glioblastoma Multiforme (GBM) is the most prevalent kind of adult malignant glioma. The World Health Organization (WHO) grading system, which goes from grade I (least aggressive) to grade IV (most aggressive), is used to classify gliomas. Although these regimens are still under debate, the usual treatment for grade 2 gliomas is maximal resection with single radiation therapy (RT), and for grade 3/4 malignant gliomas, it is maximal resection + RT + Temozolomide.

In Malaysia, brain tumours make up around 2% of all cancer cases, with glioma making up 15%–18% of these cases. The incidence of glioma typically rises with age, and it is somewhat greater in men than in women.

The factors attributed to market growth such as an aging population, improved diagnosis, and heightened awareness, are subsequently driving the demand for therapeutic interventions and are providing new opportunities for the expansion of the glioma therapeutics market.

With well-known medications like Temozolomide (standard first-line chemotherapy) and Avastin (for recurrent glioma), Roche and Merck have a significant advantage. Certain Indian pharmaceutical firms, such as Emcure and Sun Pharmaceuticals, offer more affordable and accessible generic versions of various chemotherapy medications to the Malaysian population, competing in the market.

Market Dynamics

Market Drivers

Rising Glioma Burden: Gliomas, especially the aggressive glioblastoma multiforme (GBM), are becoming more common in Malaysia. The aging population, better diagnosis, and more awareness are the causes of this rise. In Malaysia, there are about 520 new instances of GBM every year, which highlights the sizeable patient population and increases the demand for therapy.

Supported Healthcare Investment: Economic development and government programs such as the National Healthcare Agenda are expected to drive an increase in Malaysia's healthcare spending during the next five years. Increased funding for specialty therapies like glioma therapeutics results from this, opening up new opportunities for market growth.

Encouraged Healthcare Investment: Economic development and government programs such as the National Healthcare Agenda are expected to drive an increase in Malaysia's healthcare spending during the next five years. Increased funding for specialty therapies like glioma therapeutics results from this, opening up new opportunities for market growth.

Market Restraints

Financial constraints: Patients and their families typically face severe financial burdens as a result of the costly drugs and technology used in the treatment of gliomas, especially GBM. Costs incurred out of pocket may be high, particularly for those who lack insurance or have inadequate insurance. This difficulty is best shown by the high cost of Optune^TM, a recently licensed tumour-treating field therapy device.

Restricted Access to Specialized Care: Although improving, Malaysia's healthcare system still has gaps when it comes to the provision of specialized glioma treatment. Patients in rural locations have restricted access to the best care possible since neurosurgeons, neuro-oncologists, and sophisticated treatment facilities such as Gamma Knife radiosurgery are concentrated in urban areas.

Inadequate Insurance Coverage: In Malaysia, the majority of health insurance policies do not cover enough of the high cost of glioma therapies. Patients are left with heavy financial constraints as a result, which may prevent or postpone their access to necessary therapies.

Healthcare Policies and Regulatory Landscape

Malaysia has a dual-level healthcare system that is aimed at offering universal coverage through several means. All citizens and legal residents may get affordable basic care at public institutions, which receive significant government subsidies. However, for individuals with private insurance or enough money, the expanding private sector provides more modern treatment alternatives and shorter wait times. The competent National Pharmaceutical Regulatory Agency (NPRA) is responsible for guaranteeing the efficacy and safety of pharmaceutical goods in Malaysia. The NPRA, which was founded under the Ministry of Health, serves as the gatekeeper, carefully inspecting and approving all pharmaceuticals, medical equipment, and conventional treatments before they are given to patients. They regularly cooperate with worldwide regulatory agencies, keeping up with the most recent developments and using international best practices.

Competitive Landscape

Key Players

Roche
Novartis
Merck & Co.
Pfizer
Bristol-Myers Squibb
Emcure
Sun Pharmaceuticals
Pharmaniaga Bhd
AbbVie

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Adult Malignant Glioma Therapeutics Market Segmentation

By Disease Type

Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types

By Treatment Type

Chemotherapy
Targeted Drug Therapy
Radiation Therapy
Surgery
Gene Therapy
Immunotherapy
Vaccines

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Disease Stage

Early-Stage Tumour
Late-Stage Tumour
Palliative Care

By Route of Administration

Oral
Parenteral
Others

By End User

Hospitals
Speciality Clinics
Chemotherapy Centres
Radiotherapy Centres
Homecare
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.